Assessing miR-122's Prognostic Role in Hepatitis Complications
Versandkostenfrei!
Versandfertig in 6-10 Tagen
53,99 €
inkl. MwSt.
PAYBACK Punkte
27 °P sammeln!
Chronic hepatitis is an overarching problem of digestive diseases. According to WHO, more than 170 million people have chronic hepatitis C, and there are more than 2 billion people with evidence of ongoing or completed viral hepatitis B infection. Based on research from a large international study, the following conclusions have been drawn, namely that mortality from chronic viral hepatitis is comparable to tuberculosis, malaria and HIV. The study of new parameters for predicting the nature of the course, the rate of progression of liver fibrosis, and the risk of HCC development is of particul...
Chronic hepatitis is an overarching problem of digestive diseases. According to WHO, more than 170 million people have chronic hepatitis C, and there are more than 2 billion people with evidence of ongoing or completed viral hepatitis B infection. Based on research from a large international study, the following conclusions have been drawn, namely that mortality from chronic viral hepatitis is comparable to tuberculosis, malaria and HIV. The study of new parameters for predicting the nature of the course, the rate of progression of liver fibrosis, and the risk of HCC development is of particular importance. In this direction, great prospects are opened in the field of genomics. Circulating microRNA-122 was evaluated as potential non-invasive biomarkers of liver fibrosis activation and prognosis in patients with chronic viral hepatitis. Micro-RNAs are early potential markers for diagnosis and monitoring of liver tissue status, including fibrosis and carcinogenesis processes.
Andere Kunden interessierten sich für
